Michael S. Mulligan, MD
Dr. Michael S. Mulligan is a cardiothoracic surgeon and expert in thoracic cancers, treating advanced lung diseases including lung cancer and malignant pleural mesothelioma, at UW Medicine in Seattle, Washington. Dr. Mulligan is a nationally recognized expert in robotic thymectomy, thoracoscopic lobectomy, and video-assisted thoracic surgery (VATS). His clinical focus is lung transplantation and lung volume reduction surgery, as well as treating esophageal cancer, lung cancer, and mesothelioma.
Dr. Mulligan leads regional and national courses on VATS and has received numerous teaching awards. He was also the youngest person to be elected to the American Surgical Association.[3]
Education and Career
Dr. Mulligan attended Tufts University for his undergraduate education, then earned his medical degree at the University of Connecticut School of Medicine. He completed his internship and residency in General Surgery at Presbyterian Hospital and a residency in Thoracic Surgery at the University of Michigan. Dr. Mulligan remained at the University of Michigan to pursue fellowships in General Thoracic Surgery, Thoracic Transplantation, and Pathology and also had teaching appointments with the University of Michigan’s Department of Thoracic Surgery and Wayne State University before accepting responsibility for leading the lung transplant program at UW Medicine.[3]
Since joining UW Medicine, he has served as Chief of the Section of General Thoracic Surgery, established the second VA lung transplant program, and established and led the adult ECMO program at UWMC. He was named Chief of the Division of Cardiothoracic Surgery in 2017.[2]
Research
Dr. Mulligan is a surgeon-scientist with an NIH-funded basic science lab. His laboratory is focused on improving care and outcomes for patients with pulmonary diseases, particularly on understanding mechanisms and developing new prevention or treatment strategies by combining basic science with translational research. Specific goals include the identification of biomarkers for non-small cell lung cancer and the understanding of mechanisms that drive lung transplant tolerance and rejection.[1]
His significant publications include:[1]
- Mulligan MS, Varani J, Dame MK, Lane CL, Smith CW, Anderson DC, Ward PA. Role of ELAM-1 in Neutrophil-Mediated Lung Injury in Rats. J Clin Invest 1991, 88:1396-1406.
- Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA. Neutrophil-Dependent Acute Lung Injury: Requirement for P-selectin (GMP-140). J Clin Invest 90:1600-1607, 1992.
- Mulligan MS, Paulson JC, DeFrees S, Zheng ZL, Lowe JB, Ward PA. Protective Effects of Oligosaccharides in P-selectin-Dependent Lung Injury. Nature. 1993; 364:149-151.
- Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Rauer RB, Hugli TE, Miyasaka M, Warner RL, Johnson KJ, Ward PA. Requirement for and Role of C5A in Acute Inflammatory Lung Injury in Rats. J Clin Invest 1996; 98:503-12.
- Krishnadasan B, Naidu B, Farr A, Barnes A, Verrier E, Mulligan MS. Decreased Lung Ischemia Reperfusion Injury in Rats After Preoperative Administration of Cyclosporine and Tacrolimus. J Thorac Cardiovasc Surg. 2002; 123(4): 756- 767.
- Krishnadasan B, Naidu B, Fraga C, Verrier E, Mulligan MS. Roles of Proinflammatory Cytokines in Lung Ischemia-reperfusion Injury in Rats. J Thorac Cardiovasc Surg. 2003 Feb;125(2):261-72.
- Naidu B, Krishnadasan B, Thomas B, Van Rooijen N, Verrier E, Mulligan MS. Early activation of the Alveolar Macrophage is critical to the development of Lung Reperfusion Injury J Thorac Cardiovasc Surg 2003;126 (1): 200-207.
- Woolley SM, Farivar AS, Naidu BV, Rosengart M, Thomas R, Fraga C, Mulligan MS. Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg. 2004 Feb;127(2):376-84.
- Farviar AS, Yunosov M, Chen P, Madtes DK, Abrams A, Hwang B, Nash RA, and Mulligan MS. Optimizing a canine survival model of orthotopic lung transplantation. Transplantation Proceedings 38 (5):1638-1640, 2006.
- Wolf PS, Merry HE, Farivar AS, McCourtie AS, Mulligan MS. Stress-activated protein kinase inhibition to ameliorate lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2008 Mar;135(3):656-65.
